Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Other Non-Current Assets: 2023-2025

Historic Other Non-Current Assets for CG Oncology (CGON) over the last 2 years, with Sep 2025 value amounting to $114,000.

  • CG Oncology's Other Non-Current Assets rose 115.09% to $114,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $114,000, marking a year-over-year increase of 115.09%. This contributed to the annual value of $94,000 for FY2024, which is 97.99% down from last year.
  • Per CG Oncology's latest filing, its Other Non-Current Assets stood at $114,000 for Q3 2025, which was down 78.16% from $522,000 recorded in Q2 2025.
  • CG Oncology's Other Non-Current Assets' 5-year high stood at $4.7 million during Q4 2023, with a 5-year trough of $53,000 in Q1 2024.
  • Moreover, its 3-year median value for Other Non-Current Assets was $104,000 (2024), whereas its average is $759,000.
  • Per our database at Business Quant, CG Oncology's Other Non-Current Assets plummeted by 97.99% in 2024 and then soared by 884.91% in 2025.
  • Quarterly analysis of 3 years shows CG Oncology's Other Non-Current Assets stood at $4.7 million in 2023, then plummeted by 97.99% to $94,000 in 2024, then surged by 115.09% to $114,000 in 2025.
  • Its Other Non-Current Assets stands at $114,000 for Q3 2025, versus $522,000 for Q2 2025 and $516,000 for Q1 2025.